Big Pharma, Biotech Attack NASH Liver Illness From All Sides – Bloomberg

Big Pharma, Biotech Attack NASH Liver Illness From All Sides
Bloomberg
It's been called a “silent epidemic” that's slowly wasting away the livers of millions of Americans while doctors have a paltry understanding of the disease and no approved treatments. Non-alcoholic steatohepatitis, or NASH, is now in the sights of …
Allergan Acquires Akarna Therapeutics Adding to its Strong Development Program and Commitment to Innovation in …PR Newswire (press release)
Why Allergan Is Willing to Pay So Much Money for This BiotechFortune
Allergan to Buy Tobira Therapeutics in $1.7 Billion DealWall Street Journal
MarketWatch –CNBC –Reuters –StreetInsider.com
all 94 news articles »